Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR4 | P51679 | 1/20 | 0.32 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.31 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2657423 | 0.83 | TLR8 (0.32) | TLR8TLR7 | |
| SCHEMBL8878264 | 0.80 | TDP1 (0.35) | — | |
| SCHEMBL29878039 | 0.73 | — | — | |
| SCHEMBL2655737 | 0.73 | — | — | |
| SCHEMBL20743415 | 0.72 | KDM4E (0.30) | — | |
| SCHEMBL4921753 | 0.68 | HPGDS (0.39) | ALDH1A1L3MBTL1 | |
| SCHEMBL17773615 | 0.67 | ALDH1A1 (0.34) | CCR4ALDH1A1LMNAL3MBTL1 | |
| SCHEMBL7652331 | 0.67 | GSR (0.32) | NPSR1L3MBTL1 | |
| SCHEMBL7642619 | 0.67 | GSR (0.32) | NPSR1L3MBTL1 | |
| SCHEMBL14120504 | 0.67 | APLNR (0.37) | ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250145609-A1 | 3-SUBSTITUTED PYRIDAZINE COMPOUNDS AS SMARCA2 AND/OR SMARCA4 DEGRADERS | AURIGENE ONCOLOGY LIMITED (IN) | 2025-05-08 | — | — | US | disclosed |
| EP-4476225-A1 | 3-SUBSTITUTED PYRIDAZINE COMPOUNDS AS SMARCA2 AND/OR SMARCA4 DEGRADERS | Aurigene Oncology Limited (IN) | 2024-12-18 | — | — | EP | disclosed |
| CN-118871440-A | 3-Substituted pyridazine compounds as SMARCA2 and/or SMARCA4 degrading agents | 奥瑞基尼肿瘤有限公司 | 2024-10-29 | — | — | CN | disclosed |
| WO-2023152666-A1 | 3-SUBSTITUTED PYRIDAZINE COMPOUNDS AS SMARCA2 AND/OR SMARCA4 DEGRADERS | AURIGENE ONCOLOGY LIMITED (IN) | 2023-08-17 | — | — | WO | disclosed |
| CN-111032640-B | Herbicidal compounds | 先正达参股股份有限公司 | 2023-08-08 | — | — | CN | disclosed |
| US-11618743-B2 | Herbicidal compounds | SYNGENTA PARTICIPATIONS AG (CH) | 2023-04-04 | — | — | US | disclosed |
| US-20220125051-A1 | PRE-HARVEST DESICCATION METHOD | SYNGENTA CROP PROTECTION AG (CH) | 2022-04-28 | — | — | US | disclosed |
| EP-3668855-B1 | HERBICIDAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2021-11-10 | — | — | EP | disclosed |
| CN-113423271-A | Pre-harvest drying method | 先正达农作物保护股份公司 | 2021-09-21 | — | — | CN | disclosed |
| US-20210009561-A1 | HERBICIDAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2021-01-14 | — | — | US | disclosed |
| EP-3668855-A1 | HERBICIDAL COMPOUNDS | Syngenta Participations AG (CH) | 2020-06-24 | — | — | EP | disclosed |
| CN-111032640-A | Herbicidal compounds | 先正达参股股份有限公司 | 2020-04-17 | — | — | CN | disclosed |
| WO-2019034757-A1 | HERBICIDAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2019-02-21 | — | — | WO | disclosed |
| EP-1319659-B1 | TRIAZINONES AND MEDICINAL USE THEREOF | EISAI R&D MAN CO LTD (JP) | 2009-03-11 | — | — | EP | disclosed |
| US-20060189622-A1 | Pyridazinone and triazinone compounds and use thereof as pharmaceutical preparations | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-08-24 | — | — | US | disclosed |
| US-20030225081-A1 | Pyridazinones and triazinones and medicinal use thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2003-12-04 | — | — | US | disclosed |
| EP-1319659-A1 | PYRIDAZINONES AND TRIAZINONES AND MEDICINAL USE THEREOF | Eisai Co., Ltd. (JP) | 2003-06-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210009561-A1 | HERBICIDAL COMPOUNDS | DDT, ACHE, GSTO1 | CCR4 3852/4885TLR8 4678/4885TLR7 4633/4885 |
| US-20250145609-A1 | 3-SUBSTITUTED PYRIDAZINE COMPOUNDS AS SMARCA2 AND/OR SMARCA4 DEGRADERS | SMARCC1, SMARCC2, SMARCA4 | CCR4 2548/4885TLR8 3635/4885TLR7 3028/4885 |
| US-11618743-B2 | Herbicidal compounds | DDT, ACHE, GSTO1 | CCR4 3852/4885TLR8 4678/4885TLR7 4633/4885 |
| US-20030225081-A1 | Pyridazinones and triazinones and medicinal use thereof | GRIK1, GRIK3, GRIK2 | CCR4 400/4885TLR8 307/4885TLR7 234/4885 |
| US-20220125051-A1 | PRE-HARVEST DESICCATION METHOD | GMDS, TREH, DAD1 | CCR4 4660/4885TLR8 3831/4885TLR7 3301/4885 |
| US-20060189622-A1 | Pyridazinone and triazinone compounds and use thereof as pharmaceutical preparations | GRIK3, GRIK1, GRIK2 | CCR4 528/4885TLR8 513/4885TLR7 406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.